On July 24, 2023, Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, announced an increase in the size of its previously announced non-brokered private placement offering and that, further to its news release dated July 19, 2023, the Company had closed the private placement financing for gross proceeds of C$2,500,000 (the "Offering"). The Offering was led by Negev Capital, a psychedelic medical intervention investment fund.
Fasken advised Filament Health with a team led by Shanlee von Vegesack (Corporate Finance & Securities) and included Brandon Deans (Corporate Finance & Securities) and Sabrina Chang (Corporate Finance & Securities).
Jurisdiction
- Canada
